Omnichannel Value Proposition
1. The Problem Space
Market Access messaging in pharma has a structural problem. Value propositions are typically built as static, monolithic documents—often 40–60 pages—designed to say everything to everyone. Payers care about formulary positioning, HCPs care about clinical outcomes, and field teams need to handle real-time objections. A single rigid document can't serve all three.
Simultaneously, the brand was navigating a massive, multi-year clinical roadmap. If we built a traditional static document, it would be obsolete the moment new phase data dropped. Furthermore, we faced volatile FDA regulatory timelines—including a sudden Complete Response Letter (CRL) that halted a major launch. The team had to build a system flexible enough to absorb rapid sprint-cycle clinical updates and macro-level regulatory delays without stalling execution.
2. My Role
I architected the content system and led execution across modular content design, MLR approval strategy, Veeva workflow buildout, and field enablement. This was a cross-functional program spanning medical, regulatory, account, and digital teams—I served as the connective tissue between content strategy and technical delivery.
3. The Approach
The core decision was to stop thinking about the value proposition as a document and start thinking about it as a system.
Modular Architecture & Sprint Cycles
I deconstructed the traditional value proposition into discrete, MLR-approved content blocks. This eliminated the "60-page review cycle." As new, favorable study designs arrived, we were able to run agile sprint cycles to inject new clinical claims into specific modular blocks without reopening the entire portfolio for regulatory review.
Phase 1: MVP & Orchestration (Apr 2024)
We established the baseline modular system and launched the field execution layer. I engineered Rep-Triggered Email (RTE) workflows in Veeva CRM/CLM, allowing Key Account Managers to initiate contextually relevant follow-ups directly from their post-meeting workflow, pulling from the approved library based on payer segment.
Phase 2: PERSEUS & Digital Scaling (Aug 2024)
When the favorable PERSEUS data arrived, we rapidly integrated the new claims into the system. Concurrently, because the brand now had multiple lines of therapy to promote, we launched automated Non-Personal Promotion (NPP) messaging journeys. These journeys segmented audience careabouts, reinforcing field conversations through timed digital touchpoints.
Phase 3: Navigating the FDA CRL (2025)
We were fully staged for the May 2025 CEPHEUS launch when the FDA issued a Complete Response Letter (CRL) due to a manufacturing facility inspection. Because the architecture was modular, this didn't derail us. We rapidly adjusted content and targeting, staging the final MLR-cleared assets in a holding pattern so the field could execute a zero-day launch the moment final approval was granted.
4. Outcomes & Impact
- Most-Utilized Asset: Achieved the highest utilization rate by Key Account Managers in 2024 and 2025, registering 200% more customer engagement than the next closest portfolio asset.
- Industry Validation: Won the 2025 MM+M Gold Award for Best Use of Market Access Marketing, driven heavily by the explosive performance of the Phase 1 and Phase 2 (PERSEUS) rollouts.
- Agile Velocity: Successfully integrated massive clinical data updates via sprint cycles, drastically reducing MLR re-review times by isolating updates to specific modular blocks rather than full-document reviews.
- Cost Reduction: Established a modular architectural blueprint that enabled rapid content reuse across future campaigns, eliminating net-new production costs.
- Channel Synchronization: Unified field and digital channels for the first time, ensuring 1st-line and 2nd-line therapy messaging remained consistent across all HCP and Payer touchpoints.
5. What I'd Do Differently
The modular system was assembled and approved block by block—a process that worked but required significant manual coordination across medical, legal, and regulatory reviewers. A next version would formalize that workflow in Adobe Workfront or a comparable system with automated routing, milestone tracking, and approval chain visibility. That removes the coordination overhead from the team managing the content and puts it in the process itself.
I'd also push earlier for a next-best-action layer in Veeva—using CRM engagement signals to recommend which modular blocks a KAM should deploy next, rather than relying on their judgment alone. The data to do this existed; we just hadn't connected it to the content system yet.